What is inscripta Inc stock?
About Inscripta, Inc Stock Inscripta is a gene-editing technology company that puts researchers in control by making it easy for them to get all they need for cutting-edge, forward cell-engineering.
What is Inscripta and EquityZen?
Inscripta is headquartered in Boulder, Colo.; has offices in Pleasanton, Calif.; and is backed by Venrock, MLS Capital, NanoDimension, Foresite, Paladin Capital Group, and Mérieux Développement. EquityZen helps investors to access private companies and their employees to sell shares.
How much money has inscripta raised in 2021?
Inscripta's latest funding round in April 2021 was reported to be $150 m. In total, Inscripta has raised $409.5 m
What is inscripta’s goal?
Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal is
What is Inscripta stock?
Inscripta is the developer of a benchtop platform for scalable digital genome engineering consisting of an instrument, consumables, software, and assays, that offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Buy or sell Inscripta stock.
Who owns Inscripta?
About Inscripta Inscripta is led by several genomic technology veterans including CEO Kevin Ness, who co-founded QuantaLife and 10x Genomics, and John Stuelpnagel, the chairman of the company's board, who was co-founder and first CEO of Illumina (NYSE: ILMN) and chairman of 10x Genomics.
Where is Inscripta?
Boulder, ColoradoWe support our customers around the world from our facilities in Boulder, Colorado; San Diego and Pleasanton, California; and Copenhagen, Denmark. Throughout our own breakthroughs, business management practices and office policies, the principles we value stay the same.
Who founded Inscripta?
Inscripta, founded in 2015 by Andrew Garst, Ryan T Gill and Tanya Lipscomb, provides gene editing tools for academic and commercial customers.In 2018 Inscripta acquired Solana Biosciences, a life sciences company founded by veterans of Illumina .
What does beam therapeutics do?
Beam is pioneering the use of base editing — a potential new class of precision genetic medicines — with a vision of providing life-long cures to patients suffering from serious diseases.
What is Crispr biology?
CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it's a way of finding a specific bit of DNA inside a cell. After that, the next step in CRISPR gene editing is usually to alter that piece of DNA.
Inscripta Comparisons
olore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui of
Inscripta Signals
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.